FOR some investors, most famously Warren Buffett (pic), it’s about the most important financial metric in judging corporate success – return on capital.
The recent failure of Unilever Plc’s £50bil (US$68bil or RM286bil) bid for GlaxoSmithKline (GSK) Plc’s consumer-healthcare business brings the concept into sharp relief.
Already a subscriber? Log in
The Star Festive Promo: Get 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
